Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Pfizer has pulled its Bextra painkiller drug off the market because of findings by the Food and Drug Administration of adverse coronary side effects, the company confirmed. Bextra will also stop being sold in the European Union as a result of the latest findings.
In 2004, the New York pharmaceutical giant spent $5 million in media on the brand, per Nielsen Monitor-Plus.
Interpublic Group’s McCann Erickson in New York won the account after a review in July 2003, but it had not produced direct-to-consumer television advertising.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in